Compositions and Methods for treating ocular inflammation with less risk of increased intraocular pressure. Use

摘要

Claim 1: Use of a Dissociated glucocorticoid receptor agonist (u00f4digrau00f6) or an ester or a pharmaceutically acceptable Salt thereof for preparing medicine to Treat or manage a condition or Disorder, inflammatory Eye Disease.Where the digra has the formula (1) where a and q are selected irrespective of the group consisting of aryl and heteroaryl groups substituted and unsubstituted cycloalkyl groups, and heterocicloalquilo substituted and unsubstituted and substituted groups and heterocicloalquenilo, cicloalquenilo Cicloalquinilo groups and not replaced, heterocicloalquinilo substituted and unsubstituted,And Heterocyclic groups substituted and unsubstituted; R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched alkyl groups C1 - 15 not replaced, linear or branched alkyl groups substituted cycloalkyl groups C1 - C3 - 15, 15 were not replaced, and groups Cycloalkyl substituted C3 - 15; R3 is selected from the group consisting of hydrogen,Linear or branched alkyl groups C1 - 15 not replaced, linear or branched alkyl groups substituted cycloalkyl groups 15 - C1, C3 and heterocicloalquilo unsubstituted cycloalkyl groups 15, 15 and heterocicloalquilo C3 -, substituted aryl and heteroaryl groups, groups, groups heterociclilicos B includes a divalent Hydrocarbon amino carbonyl,,,Heterohidrocarburo or Group; and it is a Hydroxy or amino Group; and D is absent or includes a carbonyl Group, - NH -, or ID ', where r' is a linear or branched alkyl group, substituted or non substituted C1 - 15; and where R1 and R2 together can form a cycloalkyl Group C3 - 15 Replacement Gone or not replaced; where digra, a prodrug thereof,Or a pharmaceutically acceptable Salt thereof of the Ester is present in an effective amount to Treat or control the inflammatory Eye Disease, condition or Disorder; wherein the composition provides a Lower risk of increased IOP that a composition that Presid A glucocorticoidAnd where the risk is lower for a Lower Production miocilina a meshwork of a Subject that receives such a composition for the Treatment or control.Claim 2: the use of claim 1, wherein Said disease or condition, disorder selected from the group consisting of panuveu00edtis anterior uveitis, posterior uveitis, keratitis, conjunctivitis, Vernal keratoconjunctivitis, atopic keratoconjunctivitis, Corneal ulcer, edema of cor Neal, sterile corneal infiltrates, scleritis, episcleritis, blepharitis,And post-operative ocular inflammation (post Surgical) for procedures such as Fotorefractiva Keratectomy, Cataract removal surgery, implantation of intraocular lenses, laser assisted in situ keratomileusis (u00f4lasiku00f6), Conductive Keratoplasty, queratotomu00ed Radial, Dry Eye, Macular Degeneration, Diabetic Retinopathy, macular edema,Wet age-related Macular Degeneration, Dry Age related Macular Degeneration, glaucoma. Claim 2: the use of Claim 5, wherein the digra has the formula (6).Claim 7: Use of claim 6, wherein Said composition further comprises an anti-inflammatory Agent selected from the group consisting of NSAIDs, agonists of PPAR, combinations thereof, and mixtures thereof.